

Corresponding Author:	Florian Krammer
Date:	Jul 18, 2017

Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work we publish. This form is published with all life science papers and is intended to promote consistency and transparency in reporting. All life sciences submissions use this form; while some list items might not apply to an individual manuscript, all fields must be completed for clarity.

For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.

Fv	peri	ima	nt:	ء اد	أعما	σn
ᅜᄉ	heli	11116		ai u	וכאו	gn

1	Sample	0 0170

Describe how sample size was determined.

No initial power analysis was done to select the number of mice used. An n of 3 mice/group was chosen for lung titer analysis and an n of 5 mice/ group for challenge studies based on available resources and according to the general practices in the influenza field.

2. Data exclusions

Describe any data exclusions.

No data were excluded.

3. Replication

Describe whether the experimental findings were reliably reproduced.

All experiments contained at least technical duplicates. Experimental findings were reliably reproduced. Specifically, the described mAbs are now being further developed as potential therapeutics and in vivo and in vitro results could be reproduced by independent operators.

4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

Mice were randomly assigned to infection and treatment groups without a specific algorithm.

5. Blinding

Describe whether the investigators were blinded to group allocation. The researchers were not blinded to group allocation. during data collection and/or analysis.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

6. Statistical parameters

Clearly defined error bars

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).

n/a	Con	firmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.
	\boxtimes	A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
	\boxtimes	A statement indicating how many times each experiment was replicated
	\boxtimes	The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
	\boxtimes	A description of any assumptions or corrections, such as an adjustment for multiple comparisons
	\boxtimes	The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted
		A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range

See the web collection on statistics for biologists for further resources and guidance.

Software

Policy information about availability of computer code

7. Software

Describe the software used to analyze the data in this study.

Prism Version 6

For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.

Materials and reagents

Policy information about availability of materials

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

Not applicable, there are no restrictions on the materials used in this study.

9. Antibodies

the system under study (i.e. assay and species).

Describe the antibodies used and how they were validated for use in This study describes the initial characterization of monoclonal antibodies produced in mice.

> In addition, the following proprietary antibodies were used as secondary antibodies (respective catalogue numbers are provided):

- (1) Anti-mouse IgG, horseradish peroxidase linked whole antibody (from sheep)-#NXA931
- (2) Alexa Fluor 488 donkey anti-mouse IgG-#A21202

10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

MDCK - originally obtained from ATCC, maintained and passaged in the lab SP2/0 mouse myeloma cell line - originally obtained from ATCC, maintained and passaged in the lab

b. Describe the method of cell line authentication used.

None of the cell lines used in the study have been specifically authenticated.

c. Report whether the cell lines were tested for mycoplasma contamination.

All cell lines tested negative for mycoplasma.

d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.

No commonly misidentified cell lines were used in this study.

Animals and human research participants

Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines

11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

6-8 week old, female BALB/c mice (Jackson labs) were used for all experiments.

Policy information about studies involving human research participants

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

The study did not involve human research participants.